Clinical reference Biomarker Directory
Back to directory

Human Epididymis protein 4

Established

HE4 combined with CA-125 (as ROMA) helps estimate ovarian cancer risk before surgery, improving on CA-125 alone.

Also known as HE4 WFDC2
In plain language

HE4 is a protein used alongside CA-125 to help estimate how likely a pelvic mass is to be cancerous. Unlike CA-125, it isn't raised by endometriosis, which helps avoid a false alarm in women with that common, benign condition.

Biomarker & context

HE4 (WFDC2) is a protein overexpressed in epithelial ovarian cancer, used together with CA-125 to help estimate the likelihood of malignancy in women with a pelvic mass.

What it indicates

HE4 combined with CA-125 forms the FDA-approved ROMA (Risk of Ovarian Malignancy Algorithm), incorporating menopausal status; a key advantage is that HE4 is not elevated by endometriosis, unlike CA-125, helping distinguish a benign endometrioma from true malignancy.

Diagnosis & clinical testing

Measured via serum immunoassay; ROMA calculates a predicted probability of malignancy using natural-log-transformed HE4 and CA-125 values, with different formulas and thresholds for pre- and postmenopausal women.

Guiding treatment

A high ROMA score prompts referral to a gynecologic oncologist for surgical management, since outcomes are better when ovarian cancer surgery is performed by a specialist; a low score supports a more conservative, general-gynecology management approach.

Clinical significance

Not falsely elevated by endometriosis, a key advantage over CA-125 for distinguishing benign from malignant masses.

References
  1. CancerNetwork. HE4 Biomarker Test Is Approved for Use in Risk of Ovarian Malignancy Algorithm (ROMA).
  2. PMC. (2025). Comparative Meta-Analysis of CA125, HE4, RMI, and ROMA for Pre-operative Detection of Ovarian Carcinoma.